The DETECT Initiative in Early Alzheimer’s Disease: Optimizing Collaboration and Multidisciplinary Care to Facilitate Timely Diagnosis
Podcast 2: Pharmacist
Post-Test/Evaluation
Exit Survey
Questions marked with a
*
are required
20%
Contact Information
First Name
Last Name
Email Address
Credentials/Degree (MD, DO, RN, etc.)
Date of Participation
Month
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Day
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Year
2018
2019
2020
2021
2022
2023
2024
2025
Helen is an 83-year-old Caucasian woman who has experienced progressive memory decline for the past 3 years. She has to take notes to remember things, needs reminders to take her medications, and has some difficulty coming up with words. Her husband is now paying the bills and doing most of the cooking. She has a decline in awareness of current events (such as the war in Ukraine), a flat learning curve and poor recall on bedside word list memory testing, mild naming difficulties, and was concrete on proverb interpretation – an aspect of abstract thinking.
Current medications include gabapentin, fluoxetine, verapamil ER, tramadol, Tylenol, famotidine, promethazine, oxybutynin XL, and lorazepam.
The working diagnosis is neurocognitive disorder, likely early-stage Alzheimer’s disease. Which of her medications is unlikely to be contributing to her cognitive decline?
Famotidine
Promethazine
Tramadol
Oxybutynin
What is the role of the pharmacist on the team managing patients with AD?
Assess patients for contraindications to disease-modifying therapies
Identify opportunities to improve medication adherence
Recommend patients return to primary care doctor if they exhibit worsening signs of cognition
A and B
All of the above
Start
Powered by
QuestionPro
Loading...
close
drag_indicator
close
Yes
Cancel
Continue
Answer Question
Continue Without Answering
Keep Data
Discard
close